Dyadic International, Inc.

Dyadic International, Inc., operating as Dyadic Applied BioSolutions, is a global biotechnology company headquartered in Jupiter, Florida, with additional operations in the United States and a satellite office in the Netherlands. The company focuses on developing, manufacturing, and commercializing precision-engineered, animal-free recombinant proteins and enzymes. These products serve applications across life sciences, food and nutrition, and bio-industrial markets. Dyadic utilizes its proprietary microbial expression platforms, including the C1 and Dapibus™ systems, to produce these recombinant proteins. These platforms are designed for scalable and cost-effective production for use in research, diagnostics, cell culture, nutrition, and industrial biotechnology. The company collaborates with third-party consultants, contract research organizations, and manufacturing partners for specific research, development, and commercial activities. Dyadic's commercialization strategy involves direct product sales, distribution partnerships, manufacturing collaborations, and technology licensing agreements. These agreements can include annual licensing fees, milestone payments, development funding, product supply revenues, and revenue-sharing. For over two decades, Dyadic developed a gene expression platform based on the Thermothelomyces heterothallica fungus, named the C1 platform, for producing industrial enzymes and proteins. Historically, this technology was licensed to third parties like Abengoa Bioenergy, BASF SE, and Codexis, Inc., for non-pharmaceutical industrial applications. Following the sale of certain industrial technology assets to Danisco USA (DuPont's industrial biosciences business), Dyadic retained rights to sublicense the C1 platform for human and animal pharmaceutical applications, with some exceptions, and may receive royalties from commercialized products. Post-DuPont transaction, Dyadic has focused on advancing the C1 platform for pharmaceutical uses, including vaccines and monoclonal antibodies.